What is Microdosing in this Context?
In the context of GLP-1 research compounds, microdosing refers to using doses significantly below the standard clinical trial ranges — typically 10–30% of the lowest studied therapeutic dose. The goal is to retain some degree of the metabolic and receptor activity while dramatically reducing the side effect burden that comes with full-dose protocols.
This approach has gained traction among researchers and practitioners as the GLP-1 compound category has matured, with a growing body of anecdotal and emerging clinical data suggesting meaningful benefits persist at sub-threshold doses.
Tirzepatide — The Dual Agonist
Tirzepatide is a dual GLP-1/GIP receptor agonist. The SURMOUNT clinical trial programme studied doses from 5mg to 15mg weekly, with the starting dose set at 2.5mg for tolerability. At full doses, Tirzepatide produced significant metabolic changes but also a well-documented side effect profile dominated by GI symptoms — nausea, vomiting, and diarrhoea that led to dose reductions or discontinuation in a meaningful percentage of study subjects.
Microdose range studied: 0.5–1mg weekly
- Appetite suppression observed even at sub-clinical doses
- GI side effects dramatically reduced versus 2.5mg+ doses
- Better long-term adherence in observational data
- Lower cost per research cycle — relevant for extended protocols
- Reduced concern around lean muscle mass loss at lower doses
Retatrutide — The Triple Agonist
Retatrutide is a triple receptor agonist — engaging GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 clinical trial data documented remarkable metabolic changes at 4–12mg weekly doses over 48 weeks. It represents a broader mechanism than either semaglutide (GLP-1 only) or tirzepatide (GLP-1 + GIP), with the glucagon component adding metabolic rate and lipid-clearing effects.
Microdose range studied: 0.25–0.5mg weekly
- All three receptors remain engaged even at sub-1mg doses
- Nausea and fatigue substantially reduced versus full doses
- Particularly relevant as a long-term maintenance protocol after an initial full-dose cycle
- Less data available than Tirzepatide due to earlier development stage
Metabolic benefits from GLP-1 compounds are dose-dependent. Microdosing means significantly slower results — you are getting a fraction of the receptor activation of a full-dose protocol. The gain is far better tolerability, sustainability as a long-term protocol, and reduced risk of the side effects that cause people to stop prematurely. Slower is not zero — but set your expectations accordingly.
Why Researchers Are Interested in Microdosing
The interest in GLP-1 microdosing goes beyond simply reducing side effects. Several research questions are driving attention to low-dose protocols:
- Minimum effective dose — What is the lowest dose at which clinically meaningful receptor activity is maintained?
- Maintenance vs. induction — Can a lower maintenance dose sustain results achieved at a higher induction dose?
- Muscle preservation — Lower doses may produce less of the muscle mass loss seen at higher doses, which is of significant interest in athletic and ageing research populations.
- Long-term safety profile — Chronic high-dose GLP-1 use raises questions about long-term receptor sensitivity and thyroid/pancreatic effects. Lower doses may present a more favourable long-term profile.
Tirzepatide vs Retatrutide for Microdosing Protocols
For researchers comparing the two compounds at microdose ranges, the key distinction is mechanism breadth. Tirzepatide's dual action is well-characterised with extensive clinical data. Retatrutide's triple agonism offers potentially greater metabolic breadth but with less published data at sub-clinical doses specifically.
Both compounds are available at LA LAB as login-gated products for registered account holders. Create a free account to access pricing and order details.